19 July 2024 - The outcome statement from the June 2024 DUSC meeting is now available.

The DUSC reviewed the utilisation of the following PBS listed medicines:

• Brentuximab vedotin - non-Hodgkin's lymphoma
• Galcanezumab and fremanezumab - migraine
• Semaglutide - type 2 diabetes mellitus

Read PBS News